Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, et al.: Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials (Ophthalmology 2016;123:1751-1761)
We congratulate the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group Writing Committee for publishing the 5-year results of the CATT trial of bevacizumab and ranibizumab for neovascular age-related macular degeneration.1 The CATT long-term study highlighted an average of 3.3 letters lost 5 years after starting treatment compared with 0.7 letters lost in our study,2 where a loss of just 2.7 letters was observed at 7 years.
Source: Ophthalmology - Category: Opthalmology Authors: Mark C. Gillies, Vincent Daien, Vuong Nguyen, Daniel Barthelmes Tags: Correspondence Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Avastin | Lucentis | Opthalmology | Ranibizumab Injection | Study